927892-99-7Relevant academic research and scientific papers
Novel acetamide derivatives containing 3,4-dichlorophenyl group or pharmaceutically acceptable salts thereof, preparation method therof and pharmaceutical composition for use in preventing or treating Urotensin-Ⅱ receptor activity related diseases contain
-
Paragraph 0207; 0208; 0209; 0210, (2017/01/02)
The present invention relates to an acetamide derivative including a 3,4-dichlrophenyl group, or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient for
Benzooxazolone or benzothiazolone derivatives preparation method therof, and pharmaceutical composition for use in preventing or treating Urotensin-Ⅱ receptor activity related diseases containing the same as an active ingredient
-
Paragraph 0192-0195, (2016/10/09)
The present invention relates to benzoxazolone and benzothiazolone derivatives or a pharmaceutically acceptable salt thereof, a producing method thereof, and a pharmaceutical composition for preventing or treating urotensin-II receptor activity-related diseases containing the same as an active ingredient. Benzoxazolone and benzothiazolone derivatives act as an antagonist of a urotensin-II receptor, and thus can be usefully used for preventing or treating urotensin-II receptor activity-related diseases such as congestive heart failure, heart ischemia, myocardial infarction, cardiomegalia, myofibrosis cordis, coronary artery disease, arteriosclerosis, hypertension, asthma, renal failure, diabetes, vascular inflammation, degenerative neuronal disease, stroke, pain, depression, mental illness, and cancer.COPYRIGHT KIPO 2016
Benzoxazinone derivatives containing ５―membered heteroaryl ring systems or pharmaceutically acceptable salts thereof, preparation method therof and pharmaceutical composition for use in preventing or treating Urotensin―Ⅱ receptor activity related diseases
-
Paragraph 0169-0173, (2016/11/07)
The present invention refers to 5 square heteroaryl radical including benzo jade limbs rice field derivative acceptable salt, and manufacturing method thereof agent comprising a urotensin-II receptor with in activity of disease by preventing or medicament
MORPHOLINYL AND PYRROLIDINYL ANALOGS
-
Page/Page column 28, (2008/06/13)
The present invention relates to morpholinyl, and pyrrolidinyl analogs, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.
PHENYLPYRIDONE DERIVATIVE
-
Page/Page column 38, (2008/12/05)
A compound represented by the formula (I) is contained as an active ingredient: wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like, or R1 together with a nitrogen atom to which L, Z2 and R1 are attached may form an aliphatic nitrogenated heterocyclic group and R1 and R2 together with a nitrogen atom to which they are attached may form an aliphatic nitrogenated heterocyclic group; X represents a methine group or a nitrogen atom; Y represents -CH2-O-, -CH=CH- or the like; Z1 represents a single bond, a C1-4 alkylene group or the like; Z2 represents a single bond or a C1-4 alkylene group; L represents a methylene group, a C3-8 cycloalkylene group or the like; and Ar represents an aromatic carbocyclic group or the like. The compound is useful as a pharmaceutical for a central nerves system disease, a cardiovascular disease or a metabolic disease.
Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles
McAtee, John J.,Dodson, Jason W.,Dowdell, Sarah E.,Erhard, Karl,Girard, Gerald R.,Goodman, Krista B.,Hilfiker, Mark A.,Jin, Jian,Sehon, Clark A.,Sha, Deyou,Shi, Dongchuan,Wang, Feng,Wang, Gren Z.,Wang, Ning,Wang, Yonghui,Viet, Andrew Q.,Yuan, Catherine C.K.,Zhang, Daohua,Aiyar, Nambi V.,Behm, David J.,Carballo, Luz H.,Evans, Christopher A.,Fries, Harvey E.,Nagilla, Rakesh,Roethke, Theresa J.,Xu, Xiaoping,Douglas, Stephen A.,Neeb, Michael J.
scheme or table, p. 3716 - 3719 (2009/04/04)
Lead compound 1 was successfully redesigned to provide compounds with improved pharmacokinetic profiles for this series of human urotensin-II antagonists. Replacement of the 2-pyrrolidinylmethyl-3-phenyl-piperidine core of 1 with a substituted N-methyl-2-
